Over the course of the reformulation program, tesa Labtec produced over 200 different variants of the TPM®/Oxymorphone patch to ensure they identified the optimal composition. The most promising of these new TPM®/Oxymorphone patches has increased transdermal flux in-vitro compared to the previous clinical patch, as well as enhanced physical and chemical stability across a range of standard stress tests. The performance of the patch in these assessments met or exceeded Phosphagenics’ expectations towards a commercial product. Importantly, the reformulation program produced TPM®/Oxymorphone patches appropriate for commercialisation in either the Japanese or US market. These TPM®/Oxymorphone patches have now been submitted for final stability assessments.
the jap 1 day patch didn't cut the mustard, but the 72 hr patch is set to go...a good payout from mylan may see us embark on a ph 2...if a US partner cant be found
- Forums
- ASX - By Stock
- AVE
- Mylan arbitration
Mylan arbitration, page-290
-
- There are more pages in this discussion • 35 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVE (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $9.507M |
Open | High | Low | Value | Volume |
0.3¢ | 0.3¢ | 0.3¢ | $4.366K | 1.455M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
62 | 90468113 | 0.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.3¢ | 60283238 | 17 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
57 | 86593113 | 0.002 |
22 | 73500009 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.003 | 60283238 | 17 |
0.004 | 21966015 | 19 |
0.005 | 20469333 | 10 |
0.006 | 20865067 | 11 |
0.007 | 10865221 | 9 |
Last trade - 15.51pm 26/07/2024 (20 minute delay) ? |
Featured News
AVE (ASX) Chart |